Enocef500 mg/vial

Enocef 500 mg/vial injection is indicated for the treatment of serious bacterial infections caused by susceptible Gram-positive and Gram-negative microorganisms. It is particularly used where parenteral (injectable) antibiotic therapy is required due to the severity or nature of the infection.

Approved Indications Include:

• Lower Respiratory Tract Infections — including pneumonia and bronchitis caused by susceptible organisms
• Acute Bacterial Otitis Media — middle ear infections requiring antibiotic injection therapy
• Skin and Skin Structure Infections — cellulitis, wound infections, and related soft tissue infections
• Urinary Tract Infections (UTI) — including complicated UTIs where oral therapy is insufficient
• Gonorrhea — uncomplicated gonococcal infections (single-dose treatment)
• Bacterial Septicemia — serious bloodstream infections requiring rapid, potent antibiotic coverage
• Bone and Joint Infections — osteomyelitis and septic arthritis caused by susceptible bacteria
• Meningitis — bacterial meningitis, including that caused by susceptible Gram-negative organisms
• Prevention of Postoperative Infections — perioperative prophylaxis to reduce the risk of surgical site infections
• Perioperative Infection Prophylaxis — single pre-operative dose before surgical procedures
  
  Note: Enocef 500 mg/vial is a hospital-grade injectable antibiotic. It must be prescribed and administered under the supervision of a registered physician or healthcare professional.

Third-Generation Cephalosporins

Enocef 500 mg/vial Sodium is a third-generation, broad-spectrum parenteral cephalosporin antibiotic with potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms.

Mechanism of Action

Like other beta-lactam antibiotics (cephalosporins and penicillins), Enocef 500 mg/vial kills bacteria by interfering with the synthesis of the bacterial cell wall. It binds to penicillin-binding proteins (PBPs) on the bacterial cell membrane, blocking the cross-linking of peptidoglycan chains. This disrupts cell wall integrity, ultimately causing bacterial cell lysis and death.

Beta-Lactamase Stability

A key advantage of Enocef 500 mg/vial is its high degree of stability in the presence of beta-lactamase enzymes — the primary resistance mechanism used by many bacteria against penicillins and earlier-generation cephalosporins. This makes Enocef 500 mg/vial effective against many organisms that are resistant to first- and second-generation cephalosporins.

Pharmacokinetic Properties

The exceptionally long plasma elimination half-life of 6–9 hours is a clinically significant feature of Enocef 500 mg/vial, making once-daily dosing appropriate and convenient for most patients — a major advantage over many other injectable antibiotics.

Enocef 500 mg/vial is available as a powder for injection and must be reconstituted before use. It can be administered by intramuscular (IM) injection, intravenous (IV) direct injection, or IV infusion.

Reconstitution Instructions

For Intramuscular (IM) Injection:

• 250 mg or 500 mg Enocef 500 mg/vial: dissolve in 2 mL of Lidocaine HCl 1% injection
• 1 g Enocef 500 mg/vial: dissolve in 3.5 mL of Lidocaine HCl 1% injection

Using Lidocaine HCl as the diluent for IM injection helps reduce injection-site pain.

For Intravenous (IV) Injection:

• 250 mg or 500 mg Enocef 500 mg/vial: dissolve in 5 mL of Water for Injection
• 1 g Enocef 500 mg/vial: dissolve in 10 mL of Water for Injection USP
• 2 g Enocef 500 mg/vial: dissolve in 20 mL of Water for Injection
  
  

Administration Guidelines

• IV injection should be administered slowly over 2–4 minutes
• IV tubing infusion should be given over a period of 30 minutes, at a concentration between 10 mg/mL and 40 mg/mL
• Before initiating treatment, a patient tolerance test dose should be administered to check for hypersensitivity reactions
• Freshly reconstituted solution is strongly recommended
• Reconstituted solution stability: at least 6 hours at room temperature or 24 hours at 5°C (refrigerated)

No clinically significant drug interactions have been reported for Enocef 500 mg/vial Sodium based on available prescribing information.

Clinical Note: While no formal interactions are listed, standard caution applies when co-administering Enocef 500 mg/vial with other nephrotoxic agents (e.g., aminoglycosides) or medications that may affect renal clearance. Always review the full patient medication profile before prescribing.

Enocef 500 mg/vial is generally well tolerated. However, the following adverse reactions have been reported:

Gastrointestinal

• Diarrhoea, nausea, vomiting
• Stomatitis (mouth inflammation)
• Glossitis (tongue inflammation)

Cutaneous / Skin Reactions

• Rash, pruritus (itching), urticaria (hives)
• Oedema (swelling)
• Erythema multiforme (a severe skin reaction — rare)

Haematologic (Blood) Reactions

• Eosinophilia, thrombocytopenia (low platelet count)
• Leucopenia (low white blood cell count)
• Anaemia, neutropenia

Hepatic (Liver) Reactions

• Elevated SGOT (AST) or SGPT (ALT) liver enzymes
• Bilirubinemia (elevated bilirubin levels)

Central Nervous System (CNS) Reactions

• Nervousness, confusion, sleep disturbances
• Headache, hyperactivity, hypertonia
• Dizziness
• Convulsions (rare)

Local Injection Site Reactions

• Phlebitis (vein inflammation) following intravenous administration — occurs rarely and can be minimized by administering the IV injection slowly over 2–4 minutes

Pregnancy: The safety of Enocef 500 mg/vial in human pregnancy has not been formally established. It should not be used during pregnancy unless absolutely necessary and no safer alternative is available. The prescribing physician must carefully weigh the potential benefit against the potential risk to the fetus.

Lactation (Breastfeeding): Low concentrations of Enocef 500 mg/vial are excreted into human breast milk. Enocef 500 mg/vial should be used with caution in lactating mothers, and the potential risk to the nursing infant should be considered before prescribing.

• Anaphylaxis Risk: As with all cephalosporins, anaphylactic shock can occur even after a thorough patient allergy history has been taken. Emergency management of anaphylactic shock requires immediate intravenous epinephrine (adrenaline) followed by a glucocorticoid. Facilities for emergency management must be available during administration.
• Gallbladder Sludge (Biliary Pseudolithiasis): In rare cases, ultrasound (sonogram) of the gallbladder has detected shadows suggesting sludge (biliary pseudolithiasis) during Enocef 500 mg/vial therapy. This condition is reversible upon discontinuation or completion of therapy. Even when associated with pain, conservative and non-surgical management is recommended.
• Prolonged Treatment Monitoring: During extended courses of Enocef 500 mg/vial therapy, regular blood picture (full blood count) monitoring should be performed at appropriate intervals to detect haematologic changes.
• Cross-sensitivity with Penicillins: Exercise caution in patients with a history of penicillin hypersensitivity due to possible cross-reactive allergic responses.
• Test Dose: Before starting a full course of Enocef 500 mg/vial therapy, a patient tolerance test dose should be given to check for hypersensitivity.

There is no specific antidote for Enocef 500 mg/vial overdose. Management of overdose should be symptomatic and supportive. If overdose is suspected, the patient should be monitored clinically and appropriate supportive measures initiated. Haemodialysis and peritoneal dialysis are not effective in significantly reducing Enocef 500 mg/vial serum concentrations due to its high protein binding (approximately 95%).

Neonates (Newborns):
Enocef 500 mg/vial must not be administered to premature newborns or to full-term neonates within the first 28 days of life (up to 4 weeks of age). This restriction applies regardless of the indication, due to the risk of bilirubin displacement from albumin-binding sites, which may lead to bilirubin encephalopathy (kernicterus) in neonates.

Renal and Hepatic Impairment:
No specific dose adjustment is provided in the original prescribing information; however, given that Enocef 500 mg/vial is excreted both renally (40–65%) and biliary, patients with severe combined renal and hepatic impairment should be monitored closely during therapy.